Published in PLoS One on July 29, 2013
Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients. PLoS One (2015) 1.42
Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen. Clin Pharmacokinet (2015) 0.87
Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment. Breast Cancer (Dove Med Press) (2016) 0.78
Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer. BMC Cancer (2015) 0.77
Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer. Breast Cancer Res Treat (2014) 0.77
Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene. Pharmacogenomics J (2016) 0.75
Genomic characteristics of pancreatic squamous cell carcinoma, an investigation by using high throughput sequencing after in-solution hybrid capture. Oncotarget (2017) 0.75
Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients. Breast Cancer (Dove Med Press) (2017) 0.75
Pharmacogenetics of SULT1A1. Pharmacogenomics (2014) 0.75
Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment. Pharmacogenet Genomics (2017) 0.75
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet (2001) 5.80
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst (1996) 5.28
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther (2004) 3.84
Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J (2005) 3.51
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat (2004) 3.40
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol (2010) 3.21
Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat (2005) 2.75
Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol (2007) 2.71
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol (2005) 2.41
The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics (2001) 2.21
Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther (2011) 1.98
CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics (2007) 1.97
Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst (2002) 1.58
Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol (2007) 1.55
CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem (2002) 1.53
CYP3A5 phenotype-genotype correlations in a British population. Br J Clin Pharmacol (2003) 1.47
The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics (2010) 1.44
Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res (2004) 1.31
Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines. Cancer Res (1996) 1.23
Pharmacogenetics in breast cancer therapy. Clin Cancer Res (2008) 1.19
Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics (2005) 1.17
Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.17
Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol (2007) 1.16
Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations. Biochem J (1999) 1.15
The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics (2002) 1.10
CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review. Am J Epidemiol (2004) 1.09
The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review. Health Technol Assess (2011) 1.08
Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer (2010) 1.06
Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases. Drug Metab Dispos (2005) 1.05
Regulation of MCF-7 breast cancer cell growth by beta-estradiol sulfation. Breast Cancer Res Treat (2002) 1.04
Pharmacogenetics of soluble sulfotransferases (SULTs). Naunyn Schmiedebergs Arch Pharmacol (2003) 1.00
Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics. Br J Pharmacol (2003) 1.00
Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters. Drug Metab Pharmacokinet (2011) 0.99
Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer. Cancer Epidemiol Biomarkers Prev (2005) 0.95
Very important pharmacogene summary: sulfotransferase 1A1. Pharmacogenet Genomics (2009) 0.89
Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial. Int J Mol Epidemiol Genet (2010) 0.88
Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Carcinogenesis (2007) 0.86
The CYP3A4*3 allele: is it really rare? Clin Chem (2001) 0.84
Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy. Cancer Chemother Pharmacol (2012) 0.83
Genetic polymorphisms and linkage disequilibrium of sulfotransferase SULT1A1 and SULT1A2 in a Korean population: comparison of other ethnic groups. Eur J Clin Pharmacol (2005) 0.82
Pharmacogenetically relevant polymorphisms in Portugal. Pharmacogenomics (2007) 0.80
Assessment of the impact of CYP3A polymorphisms on the formation of α-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomes. Drug Metab Dispos (2011) 0.80
CYP2D6*4 allele and breast cancer risk: is there any association? Clin Transl Oncol (2012) 0.78
Genetic polymorphisms of sulfotransferases (SULT1A1 and SULT1A2) in a Turkish population. Biochem Genet (2010) 0.77
Genetic polymorphisms of the CYP3A4, CYP3A5, CYP3A7 and CYP1A2 among the Jordanian population. Environ Toxicol Pharmacol (2012) 0.77
PPARGC1A genotype (Gly482Ser) predicts exceptional endurance capacity in European men. J Appl Physiol (1985) (2005) 1.12
'Smoking genes': a genetic association study. PLoS One (2011) 0.94
A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants. PLoS One (2010) 0.85
Bcl-2 expression in breast cancer: a comparative study at the mRNA and protein level. Anticancer Res (2007) 0.85
STR genetic diversity in a Mediterranean population from the south of the Iberian Peninsula. Ann Hum Biol (2010) 0.82
Pharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORC1 c.-1639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients. Thromb Haemost (2009) 0.82
Staphylococcus aureus bacteremic pneumonia: differences between community and nosocomial acquisition. Int J Infect Dis (2003) 0.81
Multiple structurally distinct ERα mRNA variants in zebrafish are differentially expressed by tissue type, stage of development and estrogen exposure. Gen Comp Endocrinol (2013) 0.80
High prevalence of seropositivity to a major allergen of Anisakis simplex, Ani s 1, in dyspeptic patients. Clin Diagn Lab Immunol (2004) 0.80
Synergistic role for pituitary growth hormone in the regulation of hepatic estrogen and progesterone receptors and vitellogenesis in female freshwater turtles, Chrysemys picta. Gen Comp Endocrinol (2005) 0.79
The Freshwater Mussel (Elliptio complanata) as a Sentinel Species: Vitellogenin and Steroid Receptors. Integr Comp Biol (2005) 0.79
Follow-up in healthy schoolchildren and in adolescents with Down syndrome: psycho-environmental and genetic determinants of physical activity and its impact on fitness, cardiovascular diseases, inflammatory biomarkers and mental health; the UP&DOWN study. BMC Public Health (2014) 0.79
Polymorphisms influencing muscle phenotypes in North-African and Spanish populations. Ann Hum Biol (2012) 0.78
Aerobic fitness is associated with lower risk of hospitalization in children with cystic fibrosis. Pediatr Pulmonol (2013) 0.78
Molecular subgroups of small (pT1) breast carcinomas belonging exclusively to the ductal infiltrating variety. Cancer Genomics Proteomics (2008) 0.77
[The Alliance for the Prevention of Colorectal Cancer in Spain. A civil commitment to society]. Gastroenterol Hepatol (2012) 0.77
Effect of gonadal steroids on progesterone receptor, estrogen receptor, and vitellogenin expression in male turtles (Chrysemys picta). J Exp Zool A Comp Exp Biol (2004) 0.77
CYP2D6 polymorphism screening in a selected population of Spain (La Alpujarra): no effect of geographical isolation. Ann Hum Biol (2010) 0.77
Regulation of hepatic progesterone and estrogen receptors in the female turtle, Chrysemys picta: relationship to vitellogenesis. Gen Comp Endocrinol (2004) 0.76
Genetic diversity of CYP3A4 and CYP3A5 polymorphisms in North African populations from Morocco and Tunisia. Int J Biol Markers (2015) 0.75
Proliferation measurement in breast cancer by two different methods. Anticancer Res (2006) 0.75
Frequency data of nine Y-chromosomal STR loci in a sample from central Spain. J Forensic Sci (2002) 0.75
Three Y-chromosome STR frequencies in a population from equatorial Guinea (Central Africa). J Forensic Sci (2002) 0.75
Tamoxifen therapy in breast cancer: do apolipoprotein E genotype and menopausal state affect plasma lipid changes induced by the drug? Int J Biol Markers (2013) 0.75
Identification of CYP2D6 null variants among long-stay, chronic psychiatric inpatients: is it strictly necessary? Hum Psychopharmacol (2008) 0.75